期刊
FRONTIERS IN ONCOLOGY
卷 8, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2018.00224
关键词
cancer; hypoxia-inducible factor-2; meta-analysis; prognosis; endothelial PAS domain protein-1
类别
资金
- European Research Council (ERC-CoG) [617060]
- Health Foundation Limburg
- European Research Council (ERC) [617060] Funding Source: European Research Council (ERC)
Hypoxia-inducible factor-2 alpha (HIF-2 alpha) plays an important role in tumor progression and metastasis. A number of studies have evaluated the correlation between HIF-2 alpha overexpression and clinical outcome in cancer patients but yielded inconsistent results. To comprehensively and quantitatively summarize the evidence on the capability of HIF-2 alpha to predict the prognosis of cancer patients with solid tumors, a meta-analysis was carried out. Renal cell carcinoma (CC-RCC) was separately analyzed due to an alternative mechanism of regulation. Systematic literature searches were performed in PubMed and Embase databases for relevant original articles until February 2018. Forty-nine studies with 6,052 patients were included in this study. The pooled hazard ratios (HRs) with corresponding confidence intervals were calculated to assess the prognostic value of HIF-2 alpha protein expression in tumor cells. The meta-analysis revealed strong significant negative associations between HIF-2 alpha expression and five endpoints: overall survival [HR = 1.69, 95% confidence interval (95% CI) 1.39-2.06], disease-free survival (HR = 1.87, 95% CI 1.2-2.92), disease-specific survival (HR = 1.57, 95% CI 1.06-2.34), metastasis-free survival (HR = 2.67, 95% CI 1.32-5.38), and progression-free survival (HR = 2.18, 95% CI 1.25-3.78). Subgroup analyses revealed similar associations in the majority of tumor sites. Overall, these data demonstrate a negative prognostic role of HIF-2 alpha in patients suffering from different types of solid tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据